Meeting
2020 ASCO Virtual Scientific Program
A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
Authors
Reinhard Dummer
Skin Cancer Center in the Department of Dermatology at University Hospital Zürich, Zürich, Switzerland
Reinhard Dummer , Shahneen Kaur Sandhu , Wilson H. Miller Jr., Marcus O. Butler , Christian U. Blank , Eva Muñoz-Couselo , Howard A. Burris III , Michael A. Postow , Bartosz Chmielowski , Mark R. Middleton , Carola Berking , Jessica Cecile Hassel , Anja Gesierich , Cornelia Mauch , Joseph Kleha , Ashwin Gollerkeri , Allison Harney , Michael D Pickard , Paolo Antonio Ascierto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02159066
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10022)
DOI
10.1200/JCO.2020.38.15_suppl.10022
Abstract #
10022
Poster Bd #
371
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).
First Author: Ken Kato
Poster
2014 ASCO Annual Meeting
A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma.
First Author: Alain Patrick Algazi
Poster
2014 ASCO Annual Meeting
A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).
First Author: Qing Zhou
Poster
2014 ASCO Annual Meeting
Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program.
First Author: Philippe Cassier